Literature DB >> 1375388

Lipoprotein(a) and acute-phase proteins in acute myocardial infarction.

L Slunga1, O Johnson, G H Dahlén, S Eriksson.   

Abstract

Lipoprotein(a) (Lp(a)) and the acute-phase proteins, orosomucoid, haptoglobin and alpha 1-antitrypsin, were studied in 32 patients with acute myocardial infarction. Samples were taken at admission and, after fasting overnight, on the following 6 days. In a subgroup of 21 patients total serum cholesterol, high-density lipoprotein (HDL) cholesterol and triglycerides were also estimated. In a linear regression model a significant relation between the relative values of Lp(a) and the time in days was obtained (p = 0.001). Compared with the acute-phase proteins, however, Lp(a) showed a weak increase and the individual responses were very variable. There were no correlations between the individual changes in Lp(a) and the changes in the acute-phase proteins, but Lp(a) changes correlated significantly with the changes in total cholesterol and low-density lipoprotein (LDL) cholesterol. It is suggested that the Lp(a) reaction in myocardial infarction is linked to the reaction of the lipoproteins. There may also be several clinical conditions, including different medications, which influence the Lp(a) level.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1375388     DOI: 10.3109/00365519209088771

Source DB:  PubMed          Journal:  Scand J Clin Lab Invest        ISSN: 0036-5513            Impact factor:   1.713


  8 in total

1.  Changes in Lp(a) lipoprotein levels during the treatment of hypercholesterolaemia with simvastatin.

Authors:  L Slunga; O Johnson; G H Dahlén
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Lipoprotein(a) screening in young and middle-aged patients presenting with acute coronary syndrome.

Authors:  Ayman Jubran; Anna Zetser; Barak Zafrir
Journal:  Cardiol J       Date:  2018-09-20       Impact factor: 2.737

3.  Enigmatic role of lipoprotein(a) in cardiovascular disease.

Authors:  Erdembileg Anuurad; Byambaa Enkhmaa; Lars Berglund
Journal:  Clin Transl Sci       Date:  2010-12       Impact factor: 4.689

4.  Changes in serum lipoprotein(a) in hyperlipidemic subjects undergoing long-term treatment with lipid-lowering drugs.

Authors:  A S Dobs; M Prasad; A Goldberg; M Guccione; D R Hoover
Journal:  Cardiovasc Drugs Ther       Date:  1995-10       Impact factor: 3.727

5.  Lp(a) lipoprotein levels as a predictor of risk for thrombogenic events in patients with Behçet's disease.

Authors:  A Orem; O Değer; O Memiş; S Bahadir; E Ovali; G Cimşit
Journal:  Ann Rheum Dis       Date:  1995-09       Impact factor: 19.103

6.  High levels of inflammatory biomarkers are associated with increased allele-specific apolipoprotein(a) levels in African-Americans.

Authors:  Erdembileg Anuurad; Jill Rubin; Alan Chiem; Russell P Tracy; Thomas A Pearson; Lars Berglund
Journal:  J Clin Endocrinol Metab       Date:  2008-02-05       Impact factor: 5.958

7.  Lipoprotein (a) and other Lipid Profile in Patients with Thrombotic Stroke: Is it a Reliable Marker?

Authors:  Shashidhar K Nagaraj; Pareenta Pai; Gopalakrishna Bhat; A Hemalatha
Journal:  J Lab Physicians       Date:  2011-01

8.  Monocyte subset distribution in patients with stable atherosclerosis and elevated levels of lipoprotein(a).

Authors:  Konstantin A Krychtiuk; Stefan P Kastl; Sebastian L Hofbauer; Anna Wonnerth; Georg Goliasch; Maria Ozsvar-Kozma; Katharina M Katsaros; Gerald Maurer; Kurt Huber; Elisabeth Dostal; Christoph J Binder; Stefan Pfaffenberger; Stanislav Oravec; Johann Wojta; Walter S Speidl
Journal:  J Clin Lipidol       Date:  2015-04-25       Impact factor: 4.766

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.